US Investigates German Drug Spending Cuts – Potential Retaliatory Tariffs

The United States has initiated an investigation into Germany's proposed measures to curb pharmaceutical spending, signaling potential trade friction between the two allies. U.S. Trade Representative Jamieson Greer announced Thursday that the probe will examine whether Berlin's plan to reduce drug expenditures is "unreasonable or discriminatory."

The investigation is being conducted under Section 301 of the U.S. Trade Act of 1974, a provision previously used in trade disputes with countries like China and France. Greer stated that his office will open a docket for written comments on June 25 and a public hearing is scheduled for September. "I am particularly concerned by reports that Germany is accelerating legislative measures that would further restrict its spending on innovative medicines," Greer commented.

This U.S. inquiry follows Germany's Ministry of Health's April proposal for a broad overhaul of its public health system. The aim is to address an impending fiscal deficit of approximately €20 billion ($23 billion). Initially, the plan included introducing variable discounts on medicines, but this was reportedly revised after pushback from the pharmaceutical industry, according to a German government source speaking to Reuters on Monday.

The Trump administration has pursued an aggressive trade agenda, imposing global tariffs and threatening further measures. The U.S. government has already proposed tariffs of up to 12.5% on imports from 60 countries, citing insufficient action to curb trade in goods produced with forced labor. The conclusion of the current investigation could lead to U.S. retaliatory tariffs on German imports, escalating trade tensions.

“

I am particularly concerned by reports that Germany is accelerating legislative measures that would further restrict its spending on innovative medicines.